# Efficacy of Islet After Kidney Transplantation

> **NCT00468117** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 24 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **PROCEDURE:** Islet transplantation
- **BIOLOGICAL:** Antithymocyte Globulin
- **BIOLOGICAL:** Daclizumab or Basiliximab
- **BIOLOGICAL:** Etanercept
- **BIOLOGICAL:** Allogenic human purified pancreatic islets

## Key facts

- **NCT ID:** NCT00468117
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2015-07
- **Final completion:** 2017-07-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00468117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00468117, "Efficacy of Islet After Kidney Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00468117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*